does semaglutide affect immune system and Autoimmune Disease: Safety and Clinical Guidelines Semaglutide is a GLP-1 Receptor

Large clinical trials including LEADER, SUSTAIN-6, and EXSCEL have not identified increased fracture rates with GLP-1 therapy compared to placebo

Improvements in heart health and diabetes risk also tend to reverse within a few years

Semaglutide (found in Ozempic and Wegovy) is a GLP-1 (glucagon-like peptide-1) receptor agonist, mimicking a single natural gut hormone to reduce appetite, slow gastric emptying, and improve insulin secretion

And so that's what's so fun is just, it's all good news

Key safety concerns associated with unregulated peptide use include: Hypoglycaemia GLP-1 and GIP receptor agonists have a low intrinsic risk of hypoglycaemia when used alone, but this risk increases significantly if combined with insulin or sulfonylureas